Novel Cancer Therapeutics--Overcoming Antigen Silencing

CytoCure HomeCytoCure MissionCytoCure TechnologyClinical TrialsContact Information


CytoCure LLC

Company Background


CytoCure LLC was founded in 1999 in order to capitalize on the discovery that tumors can escape immune destruction by down-regulating expression of targeted antigens. Importantly, this antigen loss, dubbed "antigen- silencing," is the result of gene regulatory events that are reversible.

CytoCure's research and development programs have identified numerous compounds which affect known cellular processes that can be used to up-regulate antigen expression.

CytoCure has submitted a patent application that claims the use of Interferon-beta to up-regulate antigen expression in combination with immunotherapy. A Clinical Immunotherapy Trial will test this combination of Interferon-beta (Dunn et al. 2007)  and immunotherapy in the treatment of malignant melanoma.